Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 13;8(28):eabn1382. doi: 10.1126/sciadv.abn1382

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

PMC Copyright notice

Fig. 6. — (A) IncuCyte live cell imaging indicates a drug synergism between RRM2 and the ATR inhibitor BAY1895543 that could not be shown in normal fibroblast cells (NIH3T3). (B) Combined RRM2-ATR inhibition leads to a significant induction of apoptosis compared to control or single compound–treated neuroblastoma cells while leaving NIH3T3 cells unaffected. (C) RT-qPCR analysis for CDKN1A, RRM2B, NOXA, PUMA, and BAX in IMR-32 and CLB-GA neuroblastoma cells following control (DMSO), single (3AP or BAY1895543), or combined (3AP and BAY1895543) drug treatment. (D) Immunoblotting for various DNA damage markers in IMR-32 and CLB-GA cells upon treatment with DMSO, 3AP, or BAY1895344 as a single agent or combined treatment of 3AP with BAY1895344.